Skip to main content
  • Home
  • The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Topic:
  • Heart Failure

Course Published On:

Course Expiry Date:

Overview

Taking the recent ACC heart failure guideline updates as its core theme, this symposium will provide a succinct overview of the changes with one of the guideline’s primary authors. We will then consider how guidelines have evolved to accommodate the growing number of foundational treatments for heart failure and how we are moving towards personalised care. We also take a look at HFpEF, and assess how our treatment options have changed and what else can be expected for this population.

 

This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.

Commercial Support

This programme is supported by an unrestricted educational grant from AstraZeneca. The scientific programme has not been influenced in any way by the sponsors.

Target Audience

This programme is intended to educate:

 

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

Upon participation in this programme physicians should be able to:

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
Register now Log in

Module

Title

Duration

Speakers

Presentation & Discussion The ACC Heart Failure Guidelines 2022: What Did We Learn? 15 mins Biykem Bozkurt (Texas, US)
Presentation & Discussion The Future of Guidelines: Towards Personalised Care 15 mins Mikhail Kosiborod (Kansas, US)
Presentation & Discussion HFpEF: The Final Chapter in the Heart Failure Story? 15 mins Andrew Coats (Warwick, UK)
Presentation & Discussion.

The ACC Heart Failure Guidelines 2022: What Did We Learn?

Duration: 15 mins

Speakers: Biykem Bozkurt (Texas, US)

Presentation & Discussion.

The Future of Guidelines: Towards Personalised Care

Duration: 15 mins

Speakers: Mikhail Kosiborod (Kansas, US)

Presentation & Discussion.

HFpEF: The Final Chapter in the Heart Failure Story?

Duration: 15 mins

Speakers: Andrew Coats (Warwick, UK)

Chair

Andrew Coats

Monash University, Australia and University of Warwick, UK

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

View full profile

Panelist

Mikhail Kosiborod

Cardiometabolic Center of Excellence , Saint Luke’s Mid America Heart Institute

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes. He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research

View full profile

Biykem Bozkurt

Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America. Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A.

View full profile

N/A

Related Courses

Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
  • Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Hypertrophic Cardiomyopathy in Review: Highlights of ACC 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice
  • 0.75 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021
  • 0.50 AMA PRA Credit

Learning objectives

  • Identify patients likely to benefit from invasive procedures versus pharmacological treatment
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
See more
Hypertrophic Cardiomyopathy in Review: Highlights 2019-2021
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments
See more
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
  • 1.00 MMA

Learning objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients
See more
Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme
  • 1.00 MMA

Learning objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more